Explore 130+ historical metrics & ratios
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
BICO Group is a Swedish bioconvergence company providing bioprinting, bioreactor systems, and laboratory automation equipment for cell-based research and regenerative medicine applications. The company operates through three segments: Bioprinting (Cellink brand), Biosciences (laboratory instruments), and Bioautomation (liquid handling systems), serving pharmaceutical, academic, and biotech customers globally. The stock has experienced severe distress with 43% decline over 12 months, trading at 0.7x sales and 0.6x book value despite positive free cash flow generation.
BICO generates revenue through capital equipment sales (bioprinters, bioreactors, automation systems) with typical unit prices ranging $50K-$500K, supplemented by recurring revenue from consumables (bioinks, reagents, disposables) and service contracts. The company built its portfolio through aggressive M&A (17+ acquisitions 2016-2022) creating a fragmented product portfolio. Pricing power derives from specialized bioprinting IP and switching costs once customers integrate systems into workflows, though 52% gross margin suggests moderate differentiation. The business model faces challenges from integration complexity and customer concentration in research budgets.
Bioprinting system order flow and backlog conversion rates from pharmaceutical and academic customers
Consumables attach rates and recurring revenue growth indicating installed base utilization
Restructuring progress and path to profitability following cost reduction initiatives
M&A integration success and potential portfolio rationalization or divestitures
Pharmaceutical R&D spending trends and biotech funding environment affecting capital equipment budgets
Bioprinting technology adoption remains nascent with uncertain commercialization timeline for tissue engineering applications beyond research use, limiting total addressable market expansion
Regulatory pathway complexity for bioprinted tissues and organs creates long-term uncertainty around clinical translation and revenue scaling beyond laboratory research tools
Rapid M&A-driven growth (17+ acquisitions) created integration challenges, product portfolio overlap, and potential goodwill impairment risk given current 0.6x price-to-book valuation
Fragmented competitive landscape with specialized competitors in each segment (3D Systems in bioprinting, Sartorius in bioreactors, Tecan in liquid handling) offering focused solutions versus BICO's broad portfolio
Large life sciences incumbents (Thermo Fisher, Danaher, Agilent) possess greater resources, established customer relationships, and ability to bundle bioprinting/automation into comprehensive laboratory solutions
Technology obsolescence risk as bioprinting and automation technologies evolve rapidly, requiring continuous R&D investment despite current unprofitability
Negative ROE (-27.6%) and ROA (-28.6%) indicate value destruction and inefficient capital allocation from acquisition strategy, raising concerns about asset quality and potential write-downs
Debt/equity ratio of 0.72 combined with negative operating margins creates refinancing risk if credit markets tighten or operational performance deteriorates further
Severely depressed market capitalization ($0.1B) relative to revenue ($1.9B) suggests going-concern concerns or forced asset sales if turnaround fails, with limited financial cushion
high - BICO's capital equipment sales are highly sensitive to discretionary research budgets at pharmaceutical companies, biotech firms, and academic institutions. During economic downturns or funding constraints, customers defer large capital purchases ($50K-$500K systems) while maintaining only essential consumables spending. The 13% revenue decline reflects this cyclical pressure as biotech funding dried up in 2024-2025 and pharmaceutical R&D budgets tightened. Academic customers are particularly sensitive to government funding cycles and grant availability.
High interest rates negatively impact BICO through multiple channels: (1) Biotech customer funding becomes scarce as venture capital shifts away from early-stage life sciences, reducing equipment demand; (2) Pharmaceutical companies face higher cost of capital, leading to R&D budget scrutiny and delayed capital expenditures; (3) BICO's own debt servicing costs increase (0.72 debt/equity ratio); (4) Valuation multiples compress as investors demand higher returns from unprofitable growth companies. The 47% six-month decline coincided with sustained elevated rates.
Moderate credit exposure through customer financing and working capital dynamics. BICO may offer extended payment terms or financing arrangements for large capital equipment purchases, creating receivables risk if biotech customers face liquidity issues. The company's own credit access is important given negative operating margins and need for working capital to support inventory (bioprinters, automation systems) and R&D investments. Tightening credit conditions reduce both customer purchasing power and BICO's financial flexibility.
value/distressed - The stock trades at extreme valuation discounts (0.7x sales, 0.6x book) suggesting deep value or special situations investors are primary holders. The 43% one-year decline, negative operating margins, and distressed market cap ($0.1B) attract turnaround specialists and distressed debt investors rather than growth investors. High volatility (47% six-month decline) and binary restructuring outcomes create event-driven opportunity profile. Institutional quality investors likely exited given governance concerns around aggressive M&A strategy and value destruction.
high - Stock exhibits extreme volatility with 47% decline in six months and 43% one-year loss, reflecting small-cap illiquidity, binary turnaround uncertainty, and high beta to biotech funding cycles. The combination of unprofitability, restructuring execution risk, and exposure to volatile life sciences capital equipment spending creates significant downside risk. Positive free cash flow provides some stability, but severely depressed valuation suggests market pricing in substantial probability of further deterioration or dilutive financing.